Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 6-wk Open-Label, Randomised, Multicentre, Phase IIIb, Parallel-Group Study, Which Describes the Renal Effects of the Lipid-Regulating Agents Rosuvastatin and Simvastatin in the Treatment of Sub's With Fredrickson Type IIa & Type IIb Dyslipidaemia, Inc. Heterozygous Familial Hypercholesterolaemia

NCT00654446 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00654446
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00654446 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 6-wk Open-Label, Randomised, Multicentre, Phase IIIb, Parallel-Group Study, Which Describes the Renal Effects of the Lipid-Regulating Agents Rosuvastatin and Simvastatin in the Treatment of Sub's With Fredrickson Type IIa & Type IIb Dyslipidaemia, Inc. Heterozygous Familial Hypercholesterolaemia
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2002
Completion date
April 30, 2004
Enrollment
442
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

fredrickson type iia & type iib dyslipidaemia